Imminent Risk for Fracture and Bone Formation Therapy
Robert G. Josse, MBBS, BSc, FACP, FRCP
Topics: Bone Formation Therapy, Fracture
Details
Objectives
- Discuss the concept of Imminent risk of fracture.
- Describe Bone formation stimulating therapy:
- a. Teriparatide
- b. Abaloparatide
- c. Romosozumab
- Review Combination & Sequential treatments.
Faculty
Robert G. Josse MBBS, BSc, FACP, FRCP
Professor of Medicine, University of Toronto
Dr. R. Josse graduated in Medicine with Honours from the University of London . He undertook Postgraduate Training at various Teaching Hospitals at the University of London and then came to Canada and completed his Endocrine Clinical Training, after which he did a Research Fellowship at the University of Toronto followed by a further Clinical Fellowship at the Massachusetts General Hospital in Boston. He holds Fellowships in Internal Medicine from the American College of Physicians, Royal College of Physicians of London and Internal Medicine and Endocrinology Fellowships from the Royal College of Physicians of Canada.He is also a fellow of the American College of Endocrinology
He is a Full Professor in the Departments of Medicine and Nutritional Sciences at the University of Toronto. He is also an adjunct scientist in the Li Ka Shing knowledge translation institute at St Michael’s Hospital ( SMH). He is the past head of the Division of Endocrinology and Metabolism and completed a term as Associate Physician-in-Chief at SMH. He is the director of the Metabolic Bone Disease and Osteoporosis Centre at SMH.He is an associate staff physician at UHN( Toronto General hospital) in the division of endocrinology and metabolism.He was the Toronto Director of the Canadian Multicentre Osteoporosis Study( CaMos). He is a consultant to ( and a past Chair of ) the Scientific Advisory Council of the Osteoporosis Society of Canada ( now Osteoporosis Canada) .He is a member of the committee of scientific advisors of the International Osteoporosis Foundation( IOF ). He is a past President of the Canadian Society of Endocrinology and Metabolism (CSEM) and was the inaugural chair of the CHE development and e-CME committee of the CSEM. He received the 2007 Distinguished Service Award of the
CSEM..He has also received the 2007 Distinction in Clinical Endocrinology award of the American College of Endocrinology. He is a past recipient of the Lindsay Fraser award of Osteoporosis Canada.He received the 2012 Queen Elizabeth 11 Diamond Jubilee award medal . In 2015 he received the clinician educator award of CSEM
His major research interests include calcium metabolism and osteoporosis as well as diabetes, and various nutritional metabolic problems. He has published/co-authored over three hundred and twenty articles in peer reviewed journals and twenty-one book chapters. He lectures widely both nationally and internationally on various endocrine and metabolic topics.